A 58-year-old woman with newly diagnosed multiple myeloma (IgG-κ type, standard-risk cytogenetics, creatinine 1.2 mg/dL, hemoglobin 10.5 g/dL) has completed 4 cycles of bortezomib-lenalidomide-dexamethasone (VRd) induction. Serum M-protein has decreased from 3.8 g/dL to 0.6 g/dL, and bone marrow plasma cells have dropped from 65% to 8%. She is medically fit. What is the most appropriate next step in management?

Explanation

## Autologous Stem Cell Transplantation in Standard-Risk MM **Key Point:** In newly diagnosed multiple myeloma (NDMM) with standard-risk cytogenetics, **autologous stem cell transplantation (ASCT) after 4–6 cycles of induction therapy is the standard of care** for transplant-eligible patients. ### Rationale for ASCT in This Patient **High-Yield:** ASCT improves **progression-free survival (PFS)** and **overall survival (OS)** in NDMM compared to chemotherapy alone, regardless of response depth after induction. **Clinical Pearl:** The goal of induction is NOT to achieve complete remission (CR) before transplant — it is to: 1. Reduce tumor burden 2. Assess chemosensitivity 3. Mobilize stem cells 4. Prepare the patient medically This patient shows **excellent response** (M-protein 3.8 → 0.6 g/dL, BM plasma cells 65% → 8%), confirming chemosensitivity and suitability for ASCT. ### Treatment Algorithm for Standard-Risk NDMM ```mermaid flowchart TD A[NDMM diagnosed<br/>Standard-risk cytogenetics]:::outcome --> B[Induction: PI + IMiD ± corticosteroid<br/>4-6 cycles]:::action B --> C{Transplant eligible?}:::decision C -->|Yes| D[Stem cell mobilization]:::action D --> E[ASCT]:::action E --> F[Consolidation ± maintenance]:::action C -->|No| G[Continuous therapy<br/>or observation]:::action F --> H[Long-term follow-up]:::outcome ``` ### Why Proceeding to ASCT is Correct | Factor | Evidence | |--------|----------| | **Transplant eligibility** | Age 58, fit, no major comorbidities ✓ | | **Induction cycles** | 4 cycles completed (standard is 4–6) ✓ | | **Response achieved** | Excellent response (M-protein ↓ 84%, BM plasma cells ↓ 87%) ✓ | | **Standard of care** | ASCT improves PFS/OS in standard-risk NDMM ✓ | | **Timing** | Proceed after induction, not after CR ✓ | **Mnemonic — ASCT Eligibility Criteria:** **A**ge <75 (usually), **S**ufficient **C**ardiopulmonary **T**oleration, no major organ dysfunction, fit performance status. ### Why Other Options Are Incorrect **Option A (Continue VRd 2 more cycles):** - Prolonging induction beyond 4–6 cycles does NOT improve outcomes and delays transplant. - Response is already excellent; further induction is unnecessary and may increase toxicity. **Option C (Maintenance lenalidomide):** - Maintenance is given **after** ASCT, not instead of it. - Skipping ASCT in a transplant-eligible patient with standard-risk disease is suboptimal. **Option D (Repeat bone marrow biopsy for CR confirmation):** - Bone marrow biopsy is not required to proceed to ASCT. - Response assessment by serum/urine M-protein and imaging is sufficient. - Delaying ASCT for confirmatory biopsy is unnecessary and reduces benefit. [cite:Harrison 21e Ch 186; NCCN Multiple Myeloma Guidelines 2023]